Skip to main content

Table 1 Effects of various inhibitors on LPS-induced bronchoconstriction in perfused rat lung

From: Cyclooxygenase-2-Dependent Bronchoconstriction in Perfused Rat Lungs Exposed to Endotoxin

Pretreatment

LPS

n

TV (ml)

CL(ml/cm H2O)

(RL cm H2O-sec/ml)

19

1.38 ± 0.23

0.16 ± 0.04

0.30 ± 0.04

LPS

24

0.44 ± 0.17a

0.05 ± 0.02a

0.65 ± 0.26a

WEB-2086

LPS

4

0.34 ± 0.11a

0.04 ± 0.03a

0.66 ± 0.29a

MK-571

LPS

3

0.39 ± 0.08a

0.03 ± 0.03a

0.83 ± 0.23a

AA-861

LPS

5

0.35 ± 0.12a

0.05 ± 0.01a

0.56 ± 0.30a

BM-13177

LPS

6

1.17 ± 0.33

0.16 ± 0.07

0.32 ± 0.05

ASA

LPS

4

1.36 ± 0.39

0.18 ± 0.07

0.31 ± 0.04

CGP-28238

LPS

3

1.16 ± 0.29

0.24 ± 0.05

0.27 ± 0.04

Dexamethasone

LPS

3

1.57 ± 0.56

0.26 ± 0.10

0.25 ± 0.03

  1. Tidal volume (TV), pulmonary compliance (CL) and pulmonary resistance (RL) 110 min after addition of vehicle, LPS or LPS plus various inhibitors. Ten minutes prior to injection of LPS (50 µ/ml), lungs were pretreated with the PAF-receptor antagonist WEB-2086 (66 µM), the leukotriene receptor antagonist MK-571 (10 µM), the 5-lipoxygenase inhibitor AA-861 (10 µM), the TX receptor antagonist BM-13177 (20 µM), the unspecific cyclooxygenase inhibitor acetyl salicylic acid (ASA, 275 µM) or the specific cyclooxygenase-2 inhibitor CGP-28238 (1 µM). Dexamethasone (10 µM) was administered 30 min before injection of LPS. Data are expressed as means ± SD. ap < 0.05 against control.